Showing results (61-70 of 185) with videos related to
Sort By:
Pageof 19
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 30, 2023
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early RespondersEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Journal of Crohn'S & Colitis|February 23, 2023
Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY studyEmily C L Wong, Parambir S Dulai, Badar Hasan, et al.Journal of Crohn'S & Colitis|January 13, 2025
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Inflammatory Bowel Diseases|June 28, 2022
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.The American Journal of Gastroenterology|January 18, 2024
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.The American Journal of Gastroenterology|April 18, 2022
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.Canadian Journal of Gastroenterology & Hepatology|July 12, 2014
Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart reviewNeeraj Narula, Diana Ulic, Raed Al-Dabbagh, et al.Inflammatory Bowel Diseases|November 24, 2025
Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.Digestive Diseases and Sciences|January 16, 2023
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical RemissionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.The American Journal of Gastroenterology|September 6, 2022
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY StudyNeeraj Narula, Emily C L Wong, John K Marshall, et al.Pageof 19